Erlotinib Induced Fatal Interstitial Lung Disease: An Underreported Toxicity

Ramy Sedhom

Authors

Ramy Sedhom

Keywords:

erlotinib, Interstitial lung disease, Rare Side effects, chemotherapy

Abstract

Lung cancer is the leading cause of cancer-related mortality around the world, with 85% of cases identified as non-small-cell lung cancer (NSCLC). Adenocarcinoma is the most common histologic subtype in the US and accounts for more than 50% of all NSCLC. Activating mutations in the epidermal growth factor receptor (EGFR) tyrosine kinase are found in approximately 15% of NSCLC adenocarcinoma in the US (and up to 62% in Asia) and is more common in nonsmokers. The presence of such a mutation is associated with a more favorable prognosis and predicts for sensitivity to EGFR tyrosine kinase inhibitors (TKIs) such as erlotinib, gefitinib, and afatinib. Treatment is well tolerated, with mild common adverse side effects of skin rash and diarrhea. However, increased experience with the use of these drugs has led to reports of rare serious adverse effects such as interstitial lung disease.

Downloads

How to Cite

Erlotinib Induced Fatal Interstitial Lung Disease: An Underreported Toxicity. (2016). Global Journal of Medical Research, 16(F5), 23-28. https://medicalresearchjournal.org/index.php/GJMR/article/view/1213

Download Citation

References

A Jemal, R Seigel, J Xu, E Ward (2010) Cancer statistics. 60(5), 277-300.

M Scaltriti, J Baselga (2006) The epidermal growth factor receptor pathway: a model for targeted therapy. 12(18), 5268-5272.

R Herbst, J Heymach, S Lippman (2008) Lung cancer. 358, 1367-1380.

Martin Cohen, John Johnson, Yeh-Fong Chen, Rajeshwari Sridhara, Richard Pazdur (2005) FDA Drug Approval Summary: Erlotinib (Tarceva®) Tablets. 10(7), 461-466.

Martin Cohen, Grant Williams, Rajeshwari Sridhara, Gang Chen, W Mcguinn, David Morse, Sophia Abraham, Atiqur Rahman, Chenyi Liang, Richard Lostritto, Amy Baird, Richard Pazdur (2004) United States Food and Drug Administration Drug Approval Summary. 10(4), 1212-1218.

Wei-Xiang Qi, Li-Na Tang, Ai-Na He, Yang Yao, Zan Shen (2013) Incidence and risk of treatment-related mortality in cancer patients treated with EGFR-TKIs: A meta-analysis of 22 phase III randomized controlled trials. 107(8), 1280-1283.

H Nasrallah, G Bar-Sela, N Haim (2012) Fatal interstitial lung disease associated with gemcitabine and ertolinib therapy for lung cancer. 29(1), 212-214.

Kelly Tammaro, Patricia Baldwin, Ante Lundberg (2005) Interstitial lung disease following erlotinib (Tarceva®) in a patient who previously tolerated gefitinib (Iressa®). 11(3), 127-130.

Katsuyuki Hotta, Katsuyuki Kiura, Nagio Takigawa, Hiroshige Yoshioka, Shingo Harita, Shoichi Kuyama, Toshiro Yonei, Keiichi Fujiwara, Tadashi Maeda, Keisuke Aoe, Hiroshi Ueoka, Haruhito Kamei, Shigeki Umemura, Tomonori Moritaka, Yoshihiko Segawa, Haruyuki Kawai, Akihiro Bessho, Katsuya Kato, Masahiro Tabata, Mitsune Tanimoto (2010) Comparison of the Incidence and Pattern of Interstitial Lung Disease During Erlotinib and Gefitinib Treatment in Japanese Patients with Non-small Cell Lung Cancer: The Okayama Lung Cancer Study Group Experience. 5(2), 179-184.

Shinsuke Aida, Seiichi Tamai, Susumu Sekiguchi, Nobuyoshi Shimizu (1994) Distribution of Epidermal Growth Factor and Epidermal Growth Factor Receptor in Human Lung: Immunohistochemical and Immunoelectron-Microscopic Studies. 61(3), 161-166.

Vincent Liu, Dorothy White, Maureen Zakowski, William Travis, Mark Kris, Michelle Ginsberg, Vincent Miller, Christopher Azzoli (2007) Pulmonary Toxicity Associated With Erlotinib. 132(3), 1042-1044.

M Peerzada, T Spiro, H Daw (2011) Pulmonary Toxicities of Tyrosine Kinase Inhibitors. 9(11), 824-836.

Chou Cl, H Ko, C Wang, C Yu, H Kuo, C Huand (2010) Erlotinibassociated near fatal interstitial pneumonitis in a patient with relapsed lung adenocarcinoma. 33(1), 100-105.

A Katzenstein, Askin Katzenstein (2006) s Surgical Pathology of Nonneoplastic Lung Disease. 32-33.

Shaohua Ren, Yuan Li, Weiwen Li, Zhongwei Zhao, Chunxian Jin, Dengke Zhang (2012) Fatal Asymmetric Interstitial Lung Disease after Erlotinib for Lung Cancer. 84(5), 431-435.

Hideomi Yamashita, W Takahashi, A Haga, K Nakagawa (2014) Radiation pneumonitis after stereotactic radiation therapy for lung cancer. 6(9), 708.

Hongqing Zhuang, Zhiyong Yuan, Jun Wang, Qinsong Pang, Lujun Zhao, Ping Wang, Hailing Hou (2014) Preliminary analysis of the risk factors for radiation pneumonitis in patients with non- small-cell lung cancer treated with concurrent erlotinib and thoracic radiotherapy. 807.